QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM)

被引:17
|
作者
Qin, Zijian [1 ]
Wang, Maolin [1 ]
Yan, Aixia [1 ]
机构
[1] Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, POB 53,15 BeiSanHuan East Rd, Beijing 100029, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatitis C virus (HCV) NS3/4A protease inhibitors; Quantitative structure-activity relationship (QSAR); Kohonen's self-organizing map (SOM); Multiple linear regression (MLR); Support vector machine (SVM); Sub-dataset analysis; PEPTIDE-BASED INHIBITORS; ALPHA-KETOAMIDES; SERINE-PROTEASE; ANTIVIRAL ACTIVITY; POTENT INHIBITORS; CRYSTAL-STRUCTURE; DISCOVERY; DESIGN; PROTEINASE; BINDING;
D O I
10.1016/j.bmcl.2017.05.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this study, quantitative structure-activity relationship (QSAR) models using various descriptor sets and training/test set selection methods were explored to predict the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by using a multiple linear regression (MLR) and a support vector machine (SVM) method. 512 HCV NS3/4A protease inhibitors and their IC50 values which were determined by the same FRET assay were collected from the reported literature to build a dataset. All the inhibitors were represented with selected nine global and 12 2D property-weighted autocorrelation descriptors calculated from the program CORINA Symphony. The dataset was divided into a training set and a test set by a random and a Kohonen's self-organizing map (SOM) method. The correlation coefficients (r(2)) of training sets and test sets were 0.75 and 0.72 for the best MLR model, 0.87 and 0.85 for the best SVM model, respectively. In addition, a series of sub-dataset models were also developed. The performances of all the best sub-dataset models were better than those of the whole dataset models. We believe that the combination of the best sub-and whole dataset SVM models can be used as reliable lead designing tools for new NS3/4A protease inhibitors scaffolds in a drug discovery pipeline. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2931 / 2938
页数:8
相关论文
共 50 条
  • [11] SEQUENCE EVOLUTION OF THE HCV NS3/4A PROTEASE DURING ACUTE HEPATITIS C VIRUS (HCV) INFECTION
    Dietz, J.
    Lutz, T.
    Knecht, G.
    Gute, P.
    Nehring, A.
    Raziorrouh, B.
    Diepolder, H.
    Zeuzem, S.
    Sarrazin, C.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S408 - S408
  • [12] QSAR and Docking Studies of HCV NS3 Serine Protease Inhibitors
    da Cunha, Elaine F. F.
    Matos, Karina S.
    Ramalho, Teodorico C.
    MEDICINAL CHEMISTRY, 2013, 9 (06) : 774 - 805
  • [13] Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry
    Pillaiyar, Thanigaimalai
    Namasivayam, Vigneshwaran
    Manickam, Manoj
    CURRENT MEDICINAL CHEMISTRY, 2016, 23 (29) : 3404 - 3447
  • [14] Optimization of the P′-region of peptide inhibitors of hepatitis C virus NS3/4A protease
    Ingallinella, P
    Bianchi, E
    Ingenito, R
    Koch, U
    Steinkühler, C
    Altamura, S
    Pessi, A
    BIOCHEMISTRY, 2000, 39 (42) : 12898 - 12906
  • [15] In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus
    Meeprasert, Arthitaya
    Rungrotmongkol, Thanyada
    Li, Mai Suan
    Hannongbua, Supot
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (21) : 3465 - 3477
  • [16] Prime site binding inhibitors of a serine protease:: NS3/4A of hepatitis C virus
    Ingallinella, P
    Fattori, D
    Altamura, S
    Steinkühler, C
    Koch, U
    Cicero, D
    Bazzo, R
    Cortese, R
    Bianchi, E
    Pessi, A
    BIOCHEMISTRY, 2002, 41 (17) : 5483 - 5492
  • [17] Furaprevir HCV NS3/4A protease inhibitor Treatment of chronic hepatitis C virus infection
    Ghosh, Prithwish
    Nehra, Vandana
    Temesgen, Zelalem
    DRUGS OF THE FUTURE, 2022, 47 (08) : 557 - 565
  • [18] Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease
    Mukhametov, Azat
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (12) : 1351 - 1361
  • [19] Cyclic Sulfones as Novel P3-Caps for Hepatitis C Virus NS3/4A (HCV NS3/4A) Protease Inhibitors: Synthesis and Evaluation of Inhibitors with Improved Potency and Pharmacokinetic Profiles
    Velazquez, Francisco
    Sannigrahi, Mousumi
    Bennett, Frank
    Lovey, Raymond G.
    Arasappan, Ashok
    Bogen, Stephane
    Nair, Latha
    Venkatraman, Srikanth
    Blackman, Melissa
    Hendrata, Siska
    Huang, Yuhua
    Huelgas, Regina
    Pinto, Patrick
    Cheng, Kuo-Chi
    Tong, Xiao
    McPhail, Andrew T.
    Njoroge, F. George
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (08) : 3075 - 3085
  • [20] NS3•4A protease as a target for interfering with hepatitis C virus replication
    Perni, RB
    DRUG NEWS & PERSPECTIVES, 2000, 13 (02) : 69 - 77